What is the current valuation of the India vaccine technologies market as of 2024?

The market valuation was $2509.65 Million in 2024. Read More

What is the projected market valuation for the India vaccine technologies market in 2035?

The projected valuation for 2035 is $7756.0 Million. Read More

What is the expected CAGR for the India vaccine technologies market during the forecast period 2025 - 2035?

The expected CAGR during this period is 10.8%. Read More

Which companies are considered key players in the India vaccine technologies market?

Key players include Pfizer, Moderna, AstraZeneca, Johnson & Johnson, Sanofi, GSK, Novavax, Merck, Bharat Biotech, and Sinovac Biotech. Read More

What are the main segments of the India vaccine technologies market?

The main segments include Type, Route of Administration, Disease Indication, Age Group, and Distribution Channel. Read More

How did the Recombinant/Conjugate/Subunit segment perform in 2024?

In 2024, the Recombinant/Conjugate/Subunit segment was valued at $1000.0 Million. Read More

What was the valuation of the Inactivated segment in 2024?

The Inactivated segment had a valuation of $800.0 Million in 2024. Read More

What is the projected growth for the Pediatric age group in the India vaccine technologies market?

The Pediatric age group is projected to grow from $1000.0 Million in 2024 to $3000.0 Million by 2035. Read More

What is the expected market size for Bacterial Diseases in 2035?

The market size for Bacterial Diseases is expected to reach $4556.0 Million by 2035. Read More

How does the distribution channel of Government Suppliers compare to others in 2024?

In 2024, Government Suppliers were valued at $1200.0 Million, indicating a strong position compared to other distribution channels. Read More

India Vaccine Technologies Market

ID: MRFR/Pharma/50290-HCR 200 Pages Rahul Gotadki Last Updated: October 19, 2026

India Vaccine Technologies Market Research Report By Type (Recombinant, Conjugate, Subunit, Inactivated, Live Attenuated, Toxoid), By Route of Administration (Parenteral, Oral), By Disease Indication (Viral Diseases, Bacterial Diseases), By Age Group (Pediatric, Adults) andBy Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others) - Growth & Industry Forecast 2025 To 2035

India Vaccine Technologies Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)10.8%

2024 Market Size$ 2,509.65 Million

2025 Market Size$ 2,780.69 Million

2035 Market Size$ 7,756 Million

Key Players

Pfizer

Moderna

AstraZeneca

Johnson & Johnson

Sanofi

GSK

Trends

Emergence of Novel Vaccine Platforms
Strengthening Regulatory Frameworks
Increased Public-Private Partnerships

Opportunities

Advancements in Biotechnology
Government Initiatives and Funding
Rising Demand for Preventive Healthcare

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Chemicals and Materials, BY Type (USD Million) | |
  1. 4.1.1 Recombinant/Conjugate/Subunit | |
  2. 4.1.2 Inactivated | |
  3. 4.1.3 Live Attenuated | |
  4. 4.1.4 Toxoid |
2. 4.2 Chemicals and Materials, BY Route of Administration (USD Million) | |
  1. 4.2.1 Parenteral | |
  2. 4.2.2 Oral |
3. 4.3 Chemicals and Materials, BY Disease Indication (USD Million) | |
  1. 4.3.1 Viral Diseases | |
  2. 4.3.2 Bacterial Diseases |
4. 4.4 Chemicals and Materials, BY Age Group (USD Million) | |
  1. 4.4.1 Pediatric | |
  2. 4.4.2 Adults |
5. 4.5 Chemicals and Materials, BY Distribution Channel (USD Million) | |
  1. 4.5.1 Hospital & Retail Pharmacies | |
  2. 4.5.2 Government Suppliers | |
  3. 4.5.3 Others 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Moderna (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 AstraZeneca (GB) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Johnson & Johnson (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Sanofi (FR) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 GSK (GB) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Novavax (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Merck (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Bharat Biotech (IN) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies | |
  10. 5.2.10 Sinovac Biotech (CN) | | |
    1. 5.2.10.1 Financial Overview | | |
    2. 5.2.10.2 Products Offered | | |
    3. 5.2.10.3 Key Developments | | |
    4. 5.2.10.4 SWOT Analysis | | |
    5. 5.2.10.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 INDIA MARKET ANALYSIS BY TYPE |
6. 6.3 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
7. 6.4 INDIA MARKET ANALYSIS BY DISEASE INDICATION |
8. 6.5 INDIA MARKET ANALYSIS BY AGE GROUP |
9. 6.6 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
10. 6.7 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS |
11. 6.8 RESEARCH PROCESS OF MRFR |
12. 6.9 DRO ANALYSIS OF CHEMICALS AND MATERIALS |
13. 6.10 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS |
14. 6.11 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS |
15. 6.12 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS |
16. 6.13 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE) |
17. 6.14 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million) |
18. 6.15 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
19. 6.16 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million) |
20. 6.17 CHEMICALS AND MATERIALS, BY DISEASE INDICATION, 2024 (% SHARE) |
21. 6.18 CHEMICALS AND MATERIALS, BY DISEASE INDICATION, 2024 TO 2035 (USD Million) |
22. 6.19 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 (% SHARE) |
23. 6.20 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 TO 2035 (USD Million) |
24. 6.21 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
25. 6.22 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million) |
26. 6.23 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
27. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
28. 7.2 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million) | |
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  3. 7.2.3 BY DISEASE INDICATION, 2025-2035 (USD Million) | |
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Million) | |
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million) |
29. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
30. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Enquiry

Customize Report

India Vaccine Technologies Market Segmentation

India Vaccine Technologies Market By Type (USD Million, 2025-2035)

Recombinant/Conjugate/Subunit
Inactivated
Live Attenuated
Toxoid

India Vaccine Technologies Market By Route of Administration (USD Million, 2025-2035)

Parenteral
Oral

India Vaccine Technologies Market By Disease Indication (USD Million, 2025-2035)

Viral Diseases
Bacterial Diseases

India Vaccine Technologies Market By Age Group (USD Million, 2025-2035)

Pediatric
Adults

India Vaccine Technologies Market By Distribution Channel (USD Million, 2025-2035)

Hospital & Retail Pharmacies
Government Suppliers
Others

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”